investors & media
bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.
With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.
Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.
NASDAQ: (common stock)
Data Provided by Refinitiv. Minimum 15 minutes delayed.
- Continued strong commercial launch for ZYNTEGLO ® and SKYSONA ® ; 22 patient starts across both programs to date – - Ended quarter with $227M in cash, cash equivalents, marketable securities and restricted cash – - Company entered into advance agreement to sell priority review voucher, ifRead more
Oral presentation details efficacy, safety and health-related quality of life data in adult and pediatric patients with sickle cell disease treated with lovo-cel in HGB-206 Group C and HGB-210 (n=47) through 5 years of follow-up (n=4) Updated long-term efficacy, safety, quality of life data andRead more
- Non-dilutive capital would strengthen Company’s financial position - SOMERVILLE, Mass. --(BUSINESS WIRE)--Oct. 30, 2023-- bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it has entered into an agreement to sell a Rare Pediatric Disease Priority ReviewRead more